Zoetis, Inc. Stock Plummets to New 52-Week Low of $113.30

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 113.30 as of March 24, 2026. This significant decline marks a challenging period for the company, which has seen its stock price decrease by 35.17% over the past year, contrasting sharply with the S&P 500's performance of 13.68% during the same timeframe. Despite the recent downturn, Zoetis maintains a robust market capitalization of USD 53,244 million and demonstrates strong financial metrics, including a price-to-earnings ratio of 20.00 and a commendable return on equity of 80.42%. The company also boasts a healthy dividend yield of 1.71% and a low debt-to-EBITDA ratio of 1.22, indicating a solid capacity to manage its debt obligations. In terms of operational performance, Zoetis has reported positive results for the last six consecutive quarters, with net sales growing at an annual rate of 8.16%. However, the stock's performance has been below par in both the long and near term, reflecting broader market challenges. The stock's 52-week high stands at USD 172.23, highlighting the volatility it has experienced over the past year.